Data shows 44 in every 100,000 residents in Harrow have active TB in Harrow.

田纳西州纳什维尔 - Harrow (NASDAQ:HROW)今日宣布,美国食品药品监督管理局已批准其新药临床研究申请,该公司计划开展TRIESENCE三期临床试验,这是一种无防腐剂的曲安奈德注射混悬液,用于治疗白内障手术后的眼部炎症和疼痛。 该公司股价目前接近52周高点54.85美元,反映出投资者对其产品线的信心。这家专注于眼科的公司市值达19.8亿美元,过去12个月营收增长48%,为股东带来了 ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow Health, Inc.'s control, including risks and uncertainties described from time to time in its ...

Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic ...

Essex County OPP are investigating a gunshot incident in a rural area of Essex. Police said a caller reported hearing what sounded like gunshots on Gore Road in Harrow on Monday evening, just before 9 ...

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its ...

Harrow’s ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy NASHVILLE, Tenn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic ...

Harrow (NASDAQ:HROW) has priced an underwritten public offering of 3.38 million shares of its common stock at a price of $17.75/share for expected gross proceeds of $60 million. The stock is down 1.37 ...